Mylan’s EpiPens is hard to be found in Canada and the UK and in severe shortage in the US. The problem is due to Pfizer, acting as a supplier to Mylan, which is experiencing issues in manufacturing enough product units in the St. Louis (Missouri) plant, operated by the Meridian Medical Technologies Inc unit (100% Pfizer). This situation has been ongoing for a long time in St. Louis, indeed the company was forced to recall several thousands of faulty units in March 2017. The Financial Times yesterday reported that Mylan has decided to send a team of experts to St. Louis, since the site’s management is apparently underestimating the problem. Mylan’s shares have remained fairly unaltered over the last three days.
(Sources: Reuters, FT)